This model demonstrated that postponing RRO by five years beyond current guideline ages (45 for BRCA1, 50 for BRCA2) results in a cumulative risk of ovarian cancer at age 70, that is comparable to the risk after RRSO at guideline age. Here, BRCA2 is linked to ovarian cancer.